Sugi Predict

Sugi Predict / Compounds / SCHEMBL1847992

SCHEMBL1847992

SCHEMBL1847992

CC(Nc1cc(N2CCN(C(=O)c3ccc(C(C)(C)C)cc3)CC2)ccc1[N+](=O)[O-])c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 14/20 0.74
▸ MAPT P10636 14/20 0.74
▸ NPSR1 Q6W5P4 6/20 0.74
▸ HTT P42858 3/20 0.74
▸ KDM4E B2RXH2 1/20 0.74
▸ RECQL P46063 1/20 0.74
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ LMNA P02545 2/20 0.68
▸ HTR6 P50406 2/20 0.66
▸ HPGD P15428 1/20 0.62
▸ KMT2A Q03164 2/20 0.61
▸ MAPK1 P28482 2/20 0.59
▸ CYP3A4 P08684 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ DCTPP1 Q9H773 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1844111 0.92 MAPT (0.80) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1844856 0.90 MAPT (0.75) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1841806 0.90 ALDH1A1 (0.75) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1843368 0.89 MAPT (0.73) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1844127 0.89 ALDH1A1 (0.73) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1849593 0.89 ALDH1A1 (0.73) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1844420 0.88 ALDH1A1 (0.71) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1844970 0.88 ALDH1A1 (0.72) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1842536 0.87 ALDH1A1 (0.70) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL1847634 0.86 ALDH1A1 (0.71) ALDH1A1MAPTNPSR1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2320897-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE Treventis Corporation (US) 2011-05-18 — — EP claimed
WO-2010025375-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE TREVENTIS CORPORATION (US) 2010-03-04 — — WO claimed
US-11568956-B2 Methods for identifying inhibitors of amyloid protein aggregation TREVENTIS CORPORATION (US) 2023-01-31 — — US disclosed
US-20190050526-A1 METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION TREVENTIS CORPORATION (US) 2019-02-14 — — US disclosed
US-20160283652-A1 METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION TREVENTIS CORPORATION (US) 2016-09-29 — — US disclosed
US-8420640-B2 Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine TREVENTIS CORPORATION (US) 2013-04-16 — — US disclosed
US-20110218200-A1 METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE TREVENTIS CORPORATION 2011-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218200-A1 METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE PSEN1, PSEN2, APP ALDH1A1 1948/4885MAPT 10/4885NPSR1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.